CL2017001077A1 - Pharmaceutical compositions comprising lobeglitazone for oral administration - Google Patents

Pharmaceutical compositions comprising lobeglitazone for oral administration

Info

Publication number
CL2017001077A1
CL2017001077A1 CL2017001077A CL2017001077A CL2017001077A1 CL 2017001077 A1 CL2017001077 A1 CL 2017001077A1 CL 2017001077 A CL2017001077 A CL 2017001077A CL 2017001077 A CL2017001077 A CL 2017001077A CL 2017001077 A1 CL2017001077 A1 CL 2017001077A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
oral administration
lobeglitazone
lobeglitazona
understanding
Prior art date
Application number
CL2017001077A
Other languages
Spanish (es)
Inventor
Dae Young Jung
Taek Hwan Shin
Min Jae Joo
Shin Jung Park
Jong Lae Lim
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55909398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001077(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of CL2017001077A1 publication Critical patent/CL2017001077A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES FARMACÉUTICAS PARA ADMINISTRACIÓN ORAL QUE COMPRENDEN LOBEGLITAZONA. LAS COMPOSICIONES FARMACÉUTICAS DE LA PRESENTE INVENCIÓN TIENEN EXCELENTE VELOCIDAD DE DISOLUCIÓN Y EXPRESAN RÁPIDOS EFECTOS FARMACOLÓGICOS AL COMPRENDER DERIVADOS DE CELULOSA.</p><p> THIS INVENTION REFERS TO PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION THAT INCLUDE LOBEGLITAZONA. THE PHARMACEUTICAL COMPOSITIONS OF THE PRESENT INVENTION HAVE EXCELLENT DISSOLUTION SPEED AND EXPRESS FAST PHARMACOLOGICAL EFFECTS WHEN UNDERSTANDING CELLULOSE DERIVATIVES. </p>

CL2017001077A 2014-11-06 2017-05-01 Pharmaceutical compositions comprising lobeglitazone for oral administration CL2017001077A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140153759A KR101721831B1 (en) 2014-11-06 2014-11-06 Pharmaceutical Compositions Comprising Lobeglitazone for Oral Administration

Publications (1)

Publication Number Publication Date
CL2017001077A1 true CL2017001077A1 (en) 2018-03-16

Family

ID=55909398

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001077A CL2017001077A1 (en) 2014-11-06 2017-05-01 Pharmaceutical compositions comprising lobeglitazone for oral administration

Country Status (7)

Country Link
KR (1) KR101721831B1 (en)
CN (1) CN107072954B (en)
CL (1) CL2017001077A1 (en)
CO (1) CO2017004382A2 (en)
PE (1) PE20170909A1 (en)
RU (1) RU2709526C2 (en)
WO (1) WO2016072748A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022212523A1 (en) * 2021-04-01 2022-10-06 Aclipse One, Inc. Treatment of kidney diseases
KR102739882B1 (en) * 2021-04-02 2024-12-06 연세대학교 원주산학협력단 Composition for treating ophthalmological diseases comprising lobeglitazone as an active ingredient
EP4511030A4 (en) * 2022-04-20 2026-04-01 Aclipse Two Inc TREATMENT OF gastrointestinal diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977158A (en) * 1996-11-28 1999-11-02 Novo Nordisk A/S Pharmaceutical formulations comprising levormeloxifene compounds
CN1326569C (en) * 2002-02-26 2007-07-18 阿斯特拉曾尼卡有限公司 Pharmaceutical formulation of IRESSA comprising a water-soluble cellulose derivative
KR100450700B1 (en) 2002-03-22 2004-10-01 주식회사종근당 Thiazolidinedione derivatives and pharmaceutical composition comprising the same
RU2442585C2 (en) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Method of diabetes treatment
SG178880A1 (en) * 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011077452A2 (en) * 2009-12-24 2011-06-30 Abbott Healthcare Private Limited Fast dissolving pharmaceutical composition comprising lornoxicam
CN102274162A (en) * 2011-08-02 2011-12-14 无锡万全医药技术有限公司 Solid composition comprising insoluble medicine and hydrophilic gel material and preparation method thereof
WO2013040164A1 (en) * 2011-09-13 2013-03-21 Biomed Valley Discoveries, Inc. Compositions and methods for treating metabolic disorders

Also Published As

Publication number Publication date
CN107072954B (en) 2023-05-26
CN107072954A (en) 2017-08-18
RU2709526C2 (en) 2019-12-18
KR20160054317A (en) 2016-05-16
WO2016072748A1 (en) 2016-05-12
CO2017004382A2 (en) 2017-07-19
KR101721831B1 (en) 2017-03-31
PE20170909A1 (en) 2017-07-12
RU2017119465A (en) 2018-12-06
RU2017119465A3 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
CY1123953T1 (en) DELAYED RELEASE COMPOSITIONS OF LINACLOTIDE
IL250196A0 (en) Solid dosage form composition for oral or sublingual administration of cannabinoids
HUE042449T2 (en) New 4-methoxypyrrole derivatives or their salts and pharmaceutical compositions containing them
IL257531A (en) Medicinal compositions containing anti-folr1 immunoconjugates
EP3256138A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MELOXICAM
DOP2018000059A (en) QUICK ACTION INSULIN COMPOSITIONS
PT3357491T (en) PHARMACEUTICAL COMPOSITION TO DISTRIBUTE AN ANIONIC DRUG
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
MX2015012833A (en) ANTIBIOTIC COMPOSITIONS OF CEFTOLOZANO.
BR112017008125A2 (en) viscosity reduction of pharmaceutical formulations
MA42991A (en) STABILIZATION OF PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN
MX2016012041A (en) ARIPIPRAZOL FORMULATIONS THAT HAVE HIGHER INJECTION SPEEDS.
EP3316685A4 (en) LYOPHILIZED PHARMACEUTICAL COMPOSITIONS
CL2017000587A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
GT201600252A (en) NAFTIRIDINADIONA DERIVATIVES
FR3027521B1 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
HUE057871T2 (en) Hyaluronan conjugates, methods and compositions containing medicinal active ingredients
EP3244930A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING POH DERIVATIVES
PL3452441T3 (en) Alpha-truxylic acid derivatives and pharmaceutical compositions thereof
EP3318259A4 (en) STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EP3344293A4 (en) STABILIZED VACCINE COMPOSITIONS OF VLP
MA49837A (en) PHARMACEUTICAL COMPOSITIONS
MX376741B (en) PHARMACEUTICAL COMPOSITION OF SULFONAMIDE
MX385243B (en) CLEVIDIPINE NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DK3313370T3 (en) Ophthalmological pharmaceutical composition